463 Metastatic gastric cancer patient benefiting from combined radio-immunotherapy treatment displayed sustained anti-NY-ESO-1 specific T cells and expressed important immuno-modulatory markers

Maysaloun Merhi, Afsheen Raza, Varghese Inchakalody, Siveen Kodappully, Deepak Choubey, Fairooz Sahir, Sarra Mestiri, Shereena Hydrose, Niloofar Allahverdi, Munir Jalis, Allan Relecom, Lobna Al-Zaidan (+7 others)
2020 Journal for ImmunoTherapy of Cancer  
BackgroundCombined radio-immunotherapy is currently being investigated to treat cancer patients. Anti-PD-1 immunotherapy offers the prospect of long-term disease control in solid tumors. Radiotherapy has the ability to promote immunogenic cell death leading to the release of tumor antigens, increasing infiltration and activation of T cells. NY-ESO-1 is a cancer-testis antigen expressed in 20% of advanced gastric cancers and known to induce humoral and cellular immune responses in cancer
more » ... . We report on the dynamic immune response to the NY-ESO-1 antigen and important immune-related biomarkers in a metastatic gastric cancer patient treated with radiotherapy combined with anti-PD-1 pembrolizumab antibody.MethodsOur patient was an 81-year-old male diagnosed with locally advanced unresectable MMR-deficient gastric cancer having progressed to a metastatic state under a second line of systemic treatment consisting of an anti-PD-1 pembrolizumab antibody. The patient was subsequently treated by local radiotherapy administered concomitantly with anti-PD-1, with a complete response on follow-up radiologic assessment. Disease control was sustained with no further therapy for a period of 12 months before relapse (figure 1).ResultsWe have identified an NY-ESO-1-specific IFN-? secretion from the patients T cells that was significantly increased at response (****p?0.0001) (figure 2). A novel promiscuous immunogenic NY-ESO-1 peptide P39 (P153-167) restricted to the 4 patient's HLA-DQ and HLA-DP alleles was identified. Interestingly, this peptide contained the known NY-ESO-1-derived HLA-A2-02:01(P157-165) immunogenic epitope. We have also identified a CD107+ cytotoxic T cells subset within a specific CD8+/HLA-A2-NY-ESO-1 T cell population that was low at disease-progression, markedly increased at disease-resolution and significantly decreased again at disease-re-progression (figure 3). Finally, we identified 2 groups of cytokines/chemokines. Group 1 contains 5 cytokines (IFN-?, TNF-a, IL-2, IL-5 and IL-6) that were present at disease progression, significantly downregulated at disease resolution and dramatically upregulated again at disease re-progression. Group 2 contains 4 biomarkers (Perforin, sFAS, MIP-3a and CXCL-11/ITAC) that were present at disease progression, significantly upregulated at disease resolution and dramatically downregulated again at disease re-progression (figure 4).Abstract 463 Figure 1Clinical course of disease and time-points for collection of blood samples, for pembrolizumab (Pembro) cycles, radiotherapy sessions, and PET-CT imagingAbstract 463 Figure 2Enzyme-linked ImmunoSpot assay for IFN-g production by T cells from patient's peripheral blood mononuclear cellsAbstract 463 Figure 3Phenotyping and functional characterization of patient's T cells from peripheral bloodAbstract 463 Figure 4Differential expression of cytokines/chemokines in patient's plasmaConclusionsCombined radio-immunotherapy can enhance specific T cell responses to the NY-ESO-1 antigen that correlates with beneficial clinical outcome of the patient.AcknowledgementsWe acknowledge Dr. Mohamed Elkhalifa and Ms. Zahra Abdi Ashur, from the histocompatibility and immunogenetics laboratory at Hamad Medical Corporation (HMC), for performing HLA-typing on patient's blood sample. We acknowledge Dr. Prem Chandra for his help in the statistical analysis. We are grateful to the patient for his participation to the study and to the MRC at HMC for funding this project. We acknowledge Qatar National Library for supporting the publicationTrial RegistrationNOT applicableEthics ApprovalThe study was approved by the Institutional Review board committee of Hamad Medical Corporation, Doha, Qatar.ConsentThe patient signed an informed consent form to carry out the study and to publish the data.
doi:10.1136/jitc-2020-sitc2020.0463 fatcat:z6metfcjhnenxg2kay3j2wz6ty